141 related articles for article (PubMed ID: 24308500)
1. Initial treatment of transplant-ineligible patients in multiple myeloma.
Mateos MV; Leleu X; Palumbo A; San Miguel JF
Expert Rev Hematol; 2014 Feb; 7(1):67-77. PubMed ID: 24308500
[TBL] [Abstract][Full Text] [Related]
2. How should we treat newly diagnosed multiple myeloma patients?
Mateos MV; San Miguel JF
Hematology Am Soc Hematol Educ Program; 2013; 2013():488-95. PubMed ID: 24319223
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of transplant-ineligible patients with multiple myeloma].
Kizaki M
Nihon Rinsho; 2015 Jan; 73(1):95-101. PubMed ID: 25626312
[TBL] [Abstract][Full Text] [Related]
4. Evolving role of novel agents for maintenance therapy in myeloma.
Magarotto V; Palumbo A
Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
6. The importance of complete response in outcomes in myeloma.
Nooka A; Kaufman J; Lonial S
Cancer J; 2009; 15(6):465-72. PubMed ID: 20010165
[TBL] [Abstract][Full Text] [Related]
7. New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H; McCarthy P
Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
[TBL] [Abstract][Full Text] [Related]
8. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
9. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
10. Novel generation of agents with proven clinical activity in multiple myeloma.
Mateos MV; Ocio EM; San Miguel JF
Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
[TBL] [Abstract][Full Text] [Related]
11. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
13. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
14. Continuous treatment with new agents for newly diagnosed multiple myeloma.
Zou Y; Sheng Z; Lu H; Yu J
Anticancer Drugs; 2013 Jun; 24(5):527-33. PubMed ID: 23511426
[TBL] [Abstract][Full Text] [Related]
15. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Geyer S; Kabat B; Zeldenrust SR; Kumar S; Greipp PR; Fonseca R; Lust JA; Russell SJ; Kyle RA; Witzig TE; Bergsagel PL; Stewart AK; Rajkumar SV
Mayo Clin Proc; 2007 Oct; 82(10):1179-84. PubMed ID: 17908524
[TBL] [Abstract][Full Text] [Related]
18. An overview of the progress in the treatment of multiple myeloma.
Kyle RA; Rajkumar SV
Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
20. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Lonial S; Cavenagh J
Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]